Michael Tallarico1, Jared C Foster2, Drew Seisler3, Jacqueline M Lafky3, Arti Hurria4, Aminah Jatoi3, Harvey J Cohen5, Hyman B Muss6, Nancy Bartlett7, Bruce D Cheson8, Sin-Ho Jung5, John P Leonard9, John C Byrd10, Chadi Nabhan11. 1. University of Chicago Comprehensive Cancer Center, Chicago, IL, United States. 2. Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, United States. 3. Mayo Clinic, Rochester, MN, United States. 4. City of Hope, Duarte, CA, United States. 5. Duke Cancer Institute, Duke University Medical Center, Durham, NC, United States. 6. University of North Carolina at Chapel Hill, Chapel Hill, NC, United States. 7. Washington University School of Medicine, St. Louis, MO, United States. 8. MedStar Georgetown University Hospital, Washington, DC, United States. 9. Weill Medical College of Cornell University, New York, NY, United States. 10. The Ohio State Medical Center, Columbus, OH, United States. 11. Cardinal Health, Dublin, OH, United States. Electronic address: Chadi.nabhan@cardinalhealth.com.
Abstract
OBJECTIVE: Older patients with cancer suffer from chemotherapy-related toxicities more frequently than younger patients. As novel agents are being used more commonly in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), toxicities of these agents in older patients have not been well studied. Further, impact of these toxicities on outcomes in the elderly is unknown. This study aimed to answer both questions. PATIENTS AND METHODS: We reviewed 14 Alliance for Clinical Trials in Oncology trials that enrolled CLL and/or NHL patients between 2004-2014. Toxicity was assessed per the NCI-CTCAE (version 3-5). Probabilities of experiencing grade three or four hematologic and non-hematologic toxicities were modeled as a function of clinical and disease-related factors using logistic regression. RESULTS: 1199 patients (409 age ≥ 65; 790 age < 65) were analyzed; 438 received only biologic therapy (145 age ≥ 65; 293 age < 65), and 761 received biologic + chemotherapy (264 age ≥ 65; 497 age < 65). The odds of grade three or four hematologic [odds ratio (OR) 1.70; p = 0.009: 95% CI (1.57-1.84)] and non-hematologic toxicities [OR 1.47; p = 0.022; 95% CI (1.39-1.55)] were increased in older patients with CLL, as well as odds of grade three or four non-hematologic toxicities [OR 1.89; p = 0.017; 95% CI (1.64-2.17)] in older patients with NHL. Grade three or four hematologic toxicities were associated with inferior OS and PFS in older patients with NHL [HR 3.14; p = 0.006; 95% CI (2.25-4.39) for OS and 3.06; p = 0.011; 95% CI (2.10-4.45) for PFS], though not in CLL. A prognostic model predicting grade three or four toxicities was also developed. CONCLUSIONS: CLL and NHL patients ≥ 65 year encounter more toxicities than younger patients even when treated with novel biologic agents. Development of grade three or four hematologic toxicities lead to inferior PFS and OS in NHL but not in CLL.
OBJECTIVE: Older patients with cancer suffer from chemotherapy-related toxicities more frequently than younger patients. As novel agents are being used more commonly in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), toxicities of these agents in older patients have not been well studied. Further, impact of these toxicities on outcomes in the elderly is unknown. This study aimed to answer both questions. PATIENTS AND METHODS: We reviewed 14 Alliance for Clinical Trials in Oncology trials that enrolled CLL and/or NHLpatients between 2004-2014. Toxicity was assessed per the NCI-CTCAE (version 3-5). Probabilities of experiencing grade three or four hematologic and non-hematologic toxicities were modeled as a function of clinical and disease-related factors using logistic regression. RESULTS: 1199 patients (409 age ≥ 65; 790 age < 65) were analyzed; 438 received only biologic therapy (145 age ≥ 65; 293 age < 65), and 761 received biologic + chemotherapy (264 age ≥ 65; 497 age < 65). The odds of grade three or four hematologic [odds ratio (OR) 1.70; p = 0.009: 95% CI (1.57-1.84)] and non-hematologic toxicities [OR 1.47; p = 0.022; 95% CI (1.39-1.55)] were increased in older patients with CLL, as well as odds of grade three or four non-hematologic toxicities [OR 1.89; p = 0.017; 95% CI (1.64-2.17)] in older patients with NHL. Grade three or four hematologic toxicities were associated with inferior OS and PFS in older patients with NHL [HR 3.14; p = 0.006; 95% CI (2.25-4.39) for OS and 3.06; p = 0.011; 95% CI (2.10-4.45) for PFS], though not in CLL. A prognostic model predicting grade three or four toxicities was also developed. CONCLUSIONS: CLL and NHLpatients ≥ 65 year encounter more toxicities than younger patients even when treated with novel biologic agents. Development of grade three or four hematologic toxicities lead to inferior PFS and OS in NHL but not in CLL.
Authors: Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew Journal: J Clin Oncol Date: 2011-08-01 Impact factor: 44.544
Authors: Heather E Eve; Sean Carey; Sarah J Richardson; Carla C Heise; Vidya Mamidipudi; Tao Shi; John A Radford; Rebecca L Auer; Sheila H Bullard; Simon A J Rule Journal: Br J Haematol Date: 2012-08-09 Impact factor: 6.998
Authors: Natali Pflug; Jasmin Bahlo; Tait D Shanafelt; Barbara F Eichhorst; Manuela A Bergmann; Thomas Elter; Kathrin Bauer; Gebhart Malchau; Kari G Rabe; Stephan Stilgenbauer; Hartmut Döhner; Ulrich Jäger; Michael J Eckart; Georg Hopfinger; Raymonde Busch; Anna-Maria Fink; Clemens-Martin Wendtner; Kirsten Fischer; Neil E Kay; Michael Hallek Journal: Blood Date: 2014-05-05 Impact factor: 22.113
Authors: W C Wood; D R Budman; A H Korzun; M R Cooper; J Younger; R D Hart; A Moore; J A Ellerton; L Norton; C R Ferree Journal: N Engl J Med Date: 1994-05-05 Impact factor: 91.245
Authors: Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat Journal: Blood Date: 2004-05-04 Impact factor: 22.113
Authors: Araba Adjei; Jan C Buckner; Elizabeth Cathcart-Rake; Hongbin Chen; Harvey J Cohen; Dyda Dao; Jo-Ellen De Luca; Josephine Feliciano; Rachel A Freedman; Richard M Goldberg; Judith Hopkins; Joleen Hubbard; Aminah Jatoi; Meghan Karuturi; Margaret Kemeny; Gretchen G Kimmick; Heidi D Klepin; Jessica L Krok-Schoen; Jacqueline M Lafky; Jennifer G Le-Rademacher; Daneng Li; Stuart M Lichtman; Ronald Maggiore; Jeanne Mandelblatt; Vicki A Morrison; Hyman B Muss; Michael O Ojelabi; Mina S Sedrak; Niveditha Subbiah; Virginia Sun; Susan Tuttle; Noam VanderWalde; Tanya Wildes; Melisa L Wong; Jennifer Woyach Journal: J Geriatr Oncol Date: 2019-06-11 Impact factor: 3.599
Authors: Waddah B Al-Refaie; Paul A Decker; Karla V Ballman; Peter W T Pisters; Mitchell C Posner; Kelly K Hunt; Bryan Meyers; Armin D Weinberg; Heidi Nelson; Lisa Newman; Angelina Tan; Jennifer G Le-Rademacher; Arti Hurria; Aminah Jatoi Journal: Ann Surg Oncol Date: 2019-10-11 Impact factor: 5.344
Authors: Nina Kreuzberger; Johanna Aag Damen; Marialena Trivella; Lise J Estcourt; Angela Aldin; Lisa Umlauff; Maria Dla Vazquez-Montes; Robert Wolff; Karel Gm Moons; Ina Monsef; Farid Foroutan; Karl-Anton Kreuzer; Nicole Skoetz Journal: Cochrane Database Syst Rev Date: 2020-07-31